Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement ASCO SPECIAL ARTICLE

Purpose To endorse Cancer Care Ontario’s guideline on Active Surveillance for the Management of Localized Prostate Cancer. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines developed by other professional organizations. Methods The Active Surveillance for the Management of Localized Prostate Cancer guideline was reviewed for developmental rigor by methodologists. The ASCO Endorsement Panel then reviewed the content and the recommendations. Results The ASCO Endorsement Panel determined that the recommendations from the Active Surveillance for the Management of Localized Prostate Cancer guideline, published in May 2015, are clear, thorough, and based upon the most relevant scientific evidence. ASCO endorsed the Active Surveillance for the Management of Localized Prostate Cancer guideline with added qualifying statements. The Cancer Care Ontario recommendation regarding 5-alpha reductase inhibitors was not endorsed by the ASCO panel. Recommendations For most patients with low-risk (Gleason score ≤ 6) localized prostate cancer, active surveillance is the recommended disease management strategy. Factors including younger age, prostate cancer volume, patient preference, and ethnicity should be taken into account when making management decisions. Select patients with low-volume, intermediate-risk (Gleason 3 + 4 = 7) prostate cancer may be offered active surveillance. Active surveillance protocol...
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: ASCO Guidelines, Non-ASCO Guidelines, Epidemiology & Prevention, Diagnosis & Staging ASCO SPECIAL ARTICLE Source Type: research

Related Links:

Condition:   Prostate Cancer Intervention:   Procedure: Salvage Lymphnode dissection Sponsors:   Martini-Klinik am UKE GmbH;   University Hospital Hamburg, Institute of Tumor Biology Recruiting
Source: - Category: Research Source Type: clinical trials
Condition:   Prostate Cancer Interventions:   Drug: Abemaciclib 200 MG;   Drug: Atezolizumab 1200 MG in 20 ML Injection;   Drug: Abemaciclib 150 MG Sponsor:   University of Michigan Rogel Cancer Center Not yet recruiting
Source: - Category: Research Source Type: clinical trials
AbstractMen treated for prostate cancer with curative intent face a recurrence rate of up to 53% at 10  years.68Ga-PSMA imaging is a new technique that can more accurately stage cancer recurrences and facilitate personalised treatment. We evaluated the cost-effectiveness of68Ga-PSMA PET/MRI for staging men with prostate cancer biochemical recurrence. A cost-effectiveness analysis using a decision-analytic model with Markov chains was constructed.68Ga-PSMA PET/MRI was compared with usual care in staging of men with suspected prostate cancer recurrence. Men with biochemical recurrence from a study in Brisbane, Australia...
Source: Clinical and Experimental Metastasis - Category: Cancer & Oncology Source Type: research
AbstractPurposeTo compare 3D T1-weighted fast spin echo (FSE) and 3D T1-weighted gradient echo (GE) mDixon as morphologic sequences to complement diffusion-weighted imaging (DWI) for the metastatic screening in prostate cancer (PCa) patients.Materials and methodsThirty PCa patients at high risk of metastases prospectively underwent both a 3D T1 FSE (14 min) and a rapid 3D T1 GEmDixon (1 min 20 s) sequences within a WB-MRI protocol. Two readers assessed the diagnostic performance of the FSE/Fat/in-phase (IP)/IP+Fat sequences in detecting bone and node metastases. The reference standard was established by a panel of four phy...
Source: European Radiology - Category: Radiology Source Type: research
Source: Journal of Psychosocial Oncology - Category: Cancer & Oncology Authors: Source Type: research
Despite good prognosis, increased suicide rates are reported for prostate cancer. The aim of this study was to assess the risk of suicide among prostate cancer patients before and after the start of nation-wide prostate-specific antigen (PSA)-based screeni...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Risk Factor Prevalence, Injury Occurrence Source Type: news
CONCLUSION: Surgeon's personal experiences has a significant impact on the decision-making processes during preoperative assessments. However, non-patient factors such as institutional microcultures passively and actively influence decision-making process during preoperative assessment. PMID: 31872469 [PubMed - indexed for MEDLINE]
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: J Surg Oncol Source Type: research
AbstractObjectivesConventional spin-echo (SE) DWI leads to a fundamental trade-off depending on theb value: highb value provides better lesion contrast-to-noise ratio (CNR) by sacrificing signal-to-noise ratio (SNR), image quality, and quantitative reliability. A stimulated-echo (STE) DWI acquisition is evaluated for high-CNR imaging of prostate cancer while maintaining SNR and reliable apparent diffusion coefficient (ADC) mapping.MethodsIn this prospective, IRB-approved study, 27 patients with suspected prostate cancer (PCa) were scanned with three DWI sequences (SEb = 800 s/mm2, SEb = 150...
Source: European Radiology - Category: Radiology Source Type: research
An increasing number of men diagnosed with localised prostate cancer has been accompanied by more men being considered for active surveillance as a management option. Here the author provides an update on recent developments in active surveillance and changes to NICE guidance.
Source: Trends in Urology and Men's Health - Category: Urology & Nephrology Authors: Tags: Prostate disease Source Type: research
Publication date: Available online 14 February 2020Source: European UrologyAuthor(s): Maria Chiara Sighinolfi, Bernardo Rocco
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Cancer | Cancer & Oncology | Epidemiology | Prostate Cancer